Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 1373 results for social care

  1. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued Reference number: GID-TA10663

  2. The MAGEC system for spinal lengthening in children with scoliosis (MT169)

    Discontinued Reference number: GID-MT544

  3. Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)

    This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs

  4. Fungitell for antifungal treatment stratification (MIB118)

    NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .

  5. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  6. Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495]

    Discontinued Reference number: GID-TA10395

  7. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC

  8. Newly recommended CBT therapies could help children and young people deal with anxiety

    NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety

  9. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113

    In development Reference number: GID-TA11025 Expected publication date: TBC

  10. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

  11. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    In development Reference number: GID-MT567 Expected publication date: TBC

  12. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

  13. Public board meeting agenda and papers: December 2025

    Agenda and papers of the NICE public board meeting on 10 December 2025

  14. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

  15. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued Reference number: GID-TA10324